Gradient Investments LLC Makes New $692,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN

Gradient Investments LLC purchased a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 896 shares of the biopharmaceutical company’s stock, valued at approximately $692,000.

Other institutional investors also recently made changes to their positions in the company. Salomon & Ludwin LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at $31,000. Board of the Pension Protection Fund purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $31,000. Caitlin John LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $34,000. Finally, Berbice Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 300.0% during the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 60 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Sanofi & Regeneron’s Dupixent (dupilumab) was approved in Japan as the first targeted treatment for adults with bullous pemphigoid (BP). Approval was based on pivotal data showing over four times more Dupixent patients achieved sustained remission through Week 36 vs placebo; this is Dupixent’s seventh approved indication in Japan and expands its commercial footprint and near‑term revenue potential in a new specialty indication. Dupixent Japan Approval (GlobeNewswire)
• Neutral Sentiment: Multiple short‑interest reports show a reported increase in March but list short interest as 0 shares and “NaN” changes — producing a days‑to‑cover of 0.0. This appears to be a data/reporting anomaly and is unlikely to be a meaningful driver for the stock until clearer short‑interest figures are published.
• Negative Sentiment: Apogee Therapeutics reported Phase 2 data for a long‑acting eczema therapy (zumilokibart) that supports dosing every 3–6 months; Apogee shares jumped ~20% on the news. If that program advances, it represents a potential long‑term competitive threat to Dupixent in atopic dermatitis and could pressure future market share or pricing in certain segments. Apogee Phase 2 results (BioPharmaDive)

Regeneron Pharmaceuticals Trading Up 0.7%

Shares of REGN opened at $741.69 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The stock’s 50-day moving average is $764.37 and its two-hundred day moving average is $704.03. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. The stock has a market cap of $78.41 billion, a PE ratio of 17.85, a P/E/G ratio of 1.98 and a beta of 0.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter last year, the firm earned $12.07 earnings per share. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a $0.94 dividend. The ex-dividend date was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on REGN. Guggenheim raised their price objective on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Canaccord Genuity Group increased their target price on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Royal Bank Of Canada raised their price target on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a report on Monday, March 2nd. Oppenheimer reaffirmed an “outperform” rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, February 2nd. Finally, Barclays began coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, March 6th. They set an “overweight” rating and a $923.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $802.27.

Insider Activity

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the sale, the director directly owned 17,803 shares in the company, valued at $13,860,169.59. This trade represents a 0.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 5,274 shares of company stock worth $4,142,738 over the last three months. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.